Putting More Within Reach

A next‑generation wearable injector is under development to enable subcutaneous administration of large‑volume and complex biologic therapies, addressing a growing need for alternatives to traditional in‑clinic delivery methods. Designed as a component within a drug‑device combination system, it is intended to provide patients and healthcare providers with a tool that can manage higher‑volume biologics that are not easily delivered through conventional handheld injectors. The system aims to expand access to therapies that typically require longer infusion times or specialized equipment, potentially increasing convenience and supporting treatment outside clinical settings.

Development is ongoing, and future performance and availability remain subject to the usual uncertainties associated with complex medical device programs. The injector is not independently cleared or certified, as regulatory assessment will occur within the context of complete combination products.